Epilepsy and porphyria: New perspectives

Journal of Clinical Neuroscience

Volumn 11, Issue 4, 2004, Pages 356-361

  Solinas, Carlo ^a,b   Vajda, Frank J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Antiepileptic drugs; Metabolic imbalance; Pathogenesis of porphyria; Porphyria; Registry

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; COPROPORPHYRINOGEN OXIDASE; FERROCHELATASE; GABAPENTIN; HEME; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PORPHOBILINOGEN; PORPHOBILINOGEN DEAMINASE; PORPHOBILINOGEN SYNTHASE; PORPHYRIN; PROTOPORPHYRINOGEN OXIDASE; TIAGABINE; TOPIRAMATE; UROPORPHYRINOGEN DECARBOXYLASE; UROPORPHYRINOGEN III SYNTHASE; VALPROIC ACID; VIGABATRIN;

ACUTE INTERMITTENT PORPHYRIA; CLINICAL FEATURE; CONGENITAL ERYTHROPOIETIC PORPHYRIA; EPILEPSY; ERYTHROPOIETIC PROTOPORPHYRIA; FAMILY HISTORY; HEME SYNTHESIS; HEPATIC PORPHYRIA; HUMAN; HYPONATREMIA; PATHOGENESIS; PORPHYRIA; PORPHYRIA CUTANEA TARDA; PORPHYRIA VARIEGATA; PRIORITY JOURNAL; REVIEW; SEIZURE;

EID: 2342645481     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2003.08.007     Document Type: Review

References (54)

1. Ackermann HP, Scollo-Lavizzari G. EEG changes in a patient with acute intermittent porphyria and Schwartz-Bartter syndrome (SIADH. EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb 1982; 13(3): 117-120.
2. Aggarwal A, Quint DJ, Lynch JP. MR imaging of porphyric encephalopathy. AJR 1994; 41: 1300-1302.
3. Arieff AI, Llach F, Massry SG. Neurological manifestations and morbidity of hyponatremia: correlation with brain water electrolytes. Medicine 1976; 55: 121-129.
4. Arnott G, Lehembre P, Lambert P, Dequiedt F. Acute intermittent porphyria with cerebral manifestations: generalized convulsions with focal EEG abnormalities in one case; catatonic state in another case. Lille Med 1972; 17(6): 857-862.
5. Brennan MJ, Cantrill RC. Delta-aminolaevulinic acid is a potent agonist for GABA autoreceptors. Nature 1979 (9); 280(5722): 514-515.
6. Brennan MJ, Cantrill RC. Delta-aminolaevulinic acid and amino acid neurotransmitters. Mol Cell Biochem 1981 (11); 38 Spec No (Pt 1): 49-58.
7. Bylesjo I, Forsgren L, Lithner F, Boman K. Epidemiology and clinical characteristic of seizures in patients with acute intermittent porphyria. Epilepsia 1996; 37(3): 230-235.
8. Bonkowsky HL, Sinclair PR, Emery S et al. Seizure management in acute hepatic porphyria: risks for valproate and clonazepam. Neurology 1980; 30: 588-592.
9. Celik M, Forta H, Dalkilic T, Babacan G. MRI reveals reversible lesions resembling posterior reversible encephalopathy in porphyria. Neuroradiology 2002; 44(10): 839-841.
10. Crimslik HL. The little imitator-porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry 1997; 62: 319-328.
11. D'Alessandro R, Rocchi E, Cristina E, Cassanelli M, Benassi G, Pizzino D, Baldrati A, Baruzzi A. Safety of valproate in Porphyria Cutanea Tarda. Epilepsia 1988; 29(2): 159-162.
12. Deshpande SG, Kandahari KC, Narang BS, Bikchandani R, Bhutani LK. Study of certain drugs on experimental porphyria in rats. Dermatologica 1977; 154(5): 284-290.
13. De Siervi A, Rossetti MV, Parera VE, Mendez M, Varela LS, del C battle AM. Acute intermittent porphyria: biochemical and clinical analysis in the Argentinean population. Clin Chim Acta 1999; 288(1-2): 63-71.
14. Desnick RJ. The porphyrias. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (eds.) Harrison's principle of internal medicine. McGraw-Hill; 2001.
15. Desnick RJ. Congenital erythropoietic porphyria: advances in pathogenesis and treatment. Br J Hematol 2002; 117: 779-795.
16. Doss M, Schafer HJ. Carbamazepine-induced porphyria syndrome. Lancet 1983: 1026.
17. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997(18); 314(7075): 180-181.
18. Elder GH, Smith SG, Jane Smyth S. Laboratory investigation of the porphyrias. Am Clin Biochem 1990; 27: 395-412.
19. Floderus G, Shoonlingin-Jordan PM, Harper P. Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene. Clin Genet 2002; 62(4): 288-297.
20. Gaida-Hommernick B, Rieck K, Ruunge U. Oxcarbazepine in focal epilepsy and hepatic porphyria: a case report. Epilepsia 2001; 42(6): 793-795.
21. Gregersen H, Nielsen JS, Peterslund NA. Acute porphyria and multiple organ failure during treatment with lamotrigine. Ugeskr Laeger 1996; 158(28): 4091-4092.
22. Grieco A, Alfei B, Di Rocco P, Miele L, Biolcati G, Griso D, Vecchio FM, Bianco A, Gasbarrini G. Non-alcoholic steato-hepathitis induced by carbamazepine and variegate porphyria. Eur J Gastroenterol Hepatol 2001; 13(8): 973-975.
23. Hahn M, Gildemeister OS, Krauss GL, Pepe JA, Lambrecht RW, Donohue S, Bonkovsky HL. Effects of new anticonvulsant medications on porphyrin synthesis in cultured liver cells: potential implications for patients with acute porphyria. Neurology 1997; 49: 97-106.
24. Kappas A, Sassa S, Galbraith RA, Nordmann Y. The porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds.). The Metabolic Basis of Inherited Disease, seventh edn. New York, 1994.
25. King PH, Bragdon AC. MRI reveals multiple reversible cerebral lesions in an attack of acute intermittent porphyria. Neurology 1991; 41: 1300-1302.
26. Krauss G, Simmons-O'Brien E, Campbell M. Successful treatment of seizures and porphyria with gabapentin. Neurology 1995; 45: 594-595.
27. Krijt J, Krijtova H, Sanitrak J. Effect of tiagabine and topiramate on porphyrin metabolism an in vivo model of porphyria. Pharmacol Toxicol 2001; 89(1): 15-22.
28. Kupferschmidt H, Bont A, Schnorf H, Landis T, Walter E, Peter J, Krahenbuhl S, Meier PJ. Transient cortical blindness and bioccipital brain lesions in two patients with acute intermittent porphyria. Ann Intern Med 1995; 123: 598-599.
29. Lai CW, Hung TP, Lin WS. Blindness of cerebral origin in acute intermittent porphyria. Report of a case and postmortem examination. Arch Neurol 1977; 34(5): 310-312.
30. Laiwah AC, Brodie MJ, Goldberg A. Carbamazepine-induced non-hereditary acute porphyria. Lancet 1983; 25;1(8339): 1442.
31. Larson AW, Wasserstrom WR, Felsher BF, Chih JC. Posttraumatic epilepsy and acute intermittent porphyria: effect of phenytoin, carbamazepine and clonazepam. Neurology 1978; 28(8): 824-828.
32. Leo RJ, Cannuli AR. Porphyria cutanea tarda associated with carbamazepine treatment. Am J Psychiatry 1996; 153(3): 443-444.
33. McGuire GM, Macphee GJ, Thompson GG, Moore MR, Brodie MJ. Eur J Clin Invest 1988; 18(1): 29-32.
34. Meyer U, Schuurmans MM, Lindberg RLP. Acute porphyrias: pathogenesis of neurological manifestations. Sem live disease 1998; 18(1): 43-52.
35. Najm I, Ying Z, Janigro D. Mechanisms of epileptogenesis. Neurol Clin 2001: 237-250.
36. Ono T, Johno M, Kayashima K, Omori A. Anticonvulsant syndrome with multiple symptoms, including porphyria, IgA deficiency, and liver dysfunction. J Dermatol 1990; 17(11): 684-689.
37. Parsons JL, Sahn EE, Holden KR, Pai GS. Neurologic disease in a child with hepatoerythropoietic porphyria. Pediatr Dermatol 1994; 11(3): 216-221.
38. Patsalos P, Froscher W, Pisani F, van Rijn C. The importance of drug interaction in epilepsy therapy. Epilepsia 2002; 43(4): 365-385.
39. Rank JM, Carhiters R, Bloomer J. Evidence for neurological dysfunction in end-stage protoporphyric disease. Hepatology 1993; 18(6): 1656-1657.
40. Reideout JM, Wright DJ, Lim CK, Rinsler MG, Peters TJ. Carbamazepine-induced non-hereditary acute porphyria. Lancet 1983: 464.
41. Reynolds NC. Seizure management and hepatic porphyrias. Neurology 1982; 32: 1409-1410.
42. Reynolds NC. Epilepsy in porphyria. Neurology 1996; 46: 1497-1498.
43. Rocha ME, Dutra F, Bandy B, Baldini RL, Gomes SL, Faljoni-Alario A, Liria CW, Miranda T, Bechara EJ. Oxidative damage to ferritin by 5-aminolevulinic acid. Arch Biochem Biophys 2003; 409(2): 349-356.
44. Shedlofsky SI, Bonkowsky HL. Seizure management in the hepatic porphyrias: results from a cell-culture model of porphyria. Neurology 1984; 34: 399.
45. Susa S, Daimon M, Morita Y, Kitagawa M, Hirata A, Manaka H, Sasaki H, Kato T. Acute intermittent porphyria with central pontine myelinolysis and cortical laminar necrosis. Neuroradiology 1999; 41(11): 835-839.
46. Suzuki A, Aso K, Ariyoshi C, Ishimaru M. Acute intermittent porphyria and epilepsy: safety of clonazepam. Epilepsia 1992; 33(1): 108-111.
47. Tatum WO, Zachariah S. Gabapentin treatment of seizures in acute intermittent porphyria. Neurology 1995; 45: 1216-1217.
48. Thadani H, Deacon A, Peters T. Diagnosis and management of porphyria. BMJ 2000; 320: 1647-1651.
49. Tishler PV. The effect of therapeutic drugs and other pharmacologic agents on activity of porphobilinogen deaminase, the enzyme that is deficient in intermittent acute porphyria. Life Sci 1999; 65(2): 207-214.
50. Uejima E, Takahashi K, Morisaki T, Takahashi K, Ohno M, Nishida M, Moriya M, Kaido M, Abe K, Sakoda S, Yanagihara T, Kurokawa N, Azuma J. Microsomal enzyme induction and clinical aggravation of porphyria: the evaluation of human urinary 6beta-hydroxycortisol/cortisol ratio as index of hepatic CYP3A4 activity. J Clin Pharmacol 2002; 42(12): 1374-1379.
51. Vajda FJ. Gabapentin (Chapter XVI). In: Ben Menachem E, Eadie M, Vajda FJ (eds.). Antiepileptic Drugs: Pharmacology and Therapeutics, Spring; 1999 (Chapter XVI).
52. Wycoff EE, Kushner JP. Heme biosynthesis, the porphyrias and the liver. In: The Liver: Biology and Pathophysiology. Raven Press, New York; 1994.
53. Yalouris AG, Lyberatos C, Chikirigi H, Manganas D, Pappa V, Chalevelakis G, Raptis SA. Effect of starvation and Phenobarbital on the activity of liver uroporphirinogen synthetase. Ann Biol Clin 1991; 49(7): 401-403.
54. Zadra M, Grandi R, Erli LC, Mirabile D, Brambilla A. Treatment of seizures in acute intermittent porphyria: safety and efficacy of gabapentin. Seizure 1998; 7(5): 415-416.